NVO Stock Price Today (May 2026) — Novo Nordisk A/S Analysis & Key Metrics 2026-05-22
Novo Nordisk A/S (NVO) is trading at $44.96, up 1.28% today (as of May 2026). The stock continues to show early recovery signs above the short-term average, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $46.64 (3.7% upside).
- Volatility remains elevated (19.88% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (-7.60% YoY) alongside significant competitive pressures.
NVO Stock Analysis: Key Metrics & Valuation (May 2026)
Concise, actionable data for investors
Novo Nordisk A/S - Historical Price & Volume
Market Cap
Enterprise Value: $299.00B
P/E Ratio
Forward P/E: 12.76
Revenue Growth
Year over Year
Analyst Target
+3.7% upside potential
Key Investor Questions About NVO
What investors need to know before buying
Based on current market data, NVO presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 57.29)
- Fundamentals say: Challenging (declining revenue trends)
NVO's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for NVO investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $130.96B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, NVO stock traded between $35.12 and $81.44—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 19.88% annualized volatility and β=0.27, the stock exhibits low sensitivity to market moves—making NVO suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Sector Update: Healthcare Stocks Gain Late Afternoon
Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index advancing 1.1% and the
Citi Raises its Price Target on Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is one of the 10 Best Penny Stocks to Buy for Long Term. On May 11, 2026, Citi raised the firm’s price target on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to $3.10 from $2.30 and maintained a Buy rating following the company’s Q1 2026 earnings report. On May 7, 2026, Lexicon Pharmaceuticals, Inc. […]
Novo Nordisk Weighs AI Push And Wegovy Pill Rollout Against Valuation
Novo Nordisk (NYSE:NVO) has entered a partnership with OpenAI to apply artificial intelligence across drug discovery, manufacturing, and supply chain operations. The company is preparing a global rollout of the oral Wegovy weight loss pill after its US launch. Recent trial data for semaglutide and pipeline drugs such as Amycretin and CagriSema indicate further progress in obesity and metabolic disease treatments. Novo Nordisk is drawing fresh attention as it pairs an AI push with a growing...
Sector Update: Healthcare Stocks Gain Friday Afternoon
Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index advancing 0.8% and the State
European Stocks Close Higher Friday; German Q1 GDP Increases, Semiconductor Shares Gain
European stock markets closed higher Friday as the Stoxx Europe 600 rose 0.7%, Germany's DAX 40 clim
Novo Nordisk faces new GLP-1 rival as Eli Lilly's triple agonist sets weight-loss record
Citi said Eli Lilly and Co's (NYSE:LLY) experimental obesity drug retatrutide has set a new competitive benchmark for the GLP-1 weight-loss market after a pivotal trial showed patients losing 28% of their body weight over 80 weeks at the highest dose. The results from the TRIUMPH-1 trial, the...
LLY Reports Third Phase III Win for Next-Generation Obesity Drug
Eli Lilly's retatrutide delivers its third phase III win, showing up to 28.3% weight loss at 80 weeks and broader gains across obesity-related measures.
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Buoyed by Robust Corporate Earnings Season
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.5% and the actively trad
Update: Market Chatter: Novo Nordisk, Eli Lilly Weight-Loss Drugs Show Promise in Slowing, Preventing Cancer
(Updates with Novo Nordisk's response in the fourth paragraph.) Novo Nordisk's (NVO) Ozempic and
Lilly and Novo Weight-Loss Drugs Show Potential Cancer Benefits
The findings could broaden the long-term opportunity for obesity and diabetes treatments.
Frequently Asked Questions
Common investor questions about Novo Nordisk A/S
Novo Nordisk A/S (NVO) is currently trading at $44.96. The RSI (14-day) is at 57.3, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $46.64 implies 3.7% upside from current levels. Volatility is low at 19.9% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Novo Nordisk A/S (NVO): The trailing P/E ratio is 12.16, which is below the market average of ~20-22, suggesting the stock may be undervalued relative to peers. The forward P/E is 12.76. The PEG ratio is 4.82, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 6.41. Price-to-Sales is 0.63. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 12 analysts covering NVO, the consensus price target is $46.64. This represents a 3.7% upside from the current price of $44.96. The range spans from a low target of $36.05 to a high target of $65.83, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Novo Nordisk A/S (NVO) pays a dividend with a current yield of approximately 4.01%. The annualized dividend rate is $11.70 per share. The payout ratio is 42.6%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-03-30.
Key risks for Novo Nordisk A/S (NVO) investors include: 1. Declining revenue (-7.6% YoY), indicating potential business headwinds. 2. Elevated short interest (53.0% of float) suggests significant bearish sentiment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Novo Nordisk A/S's (NVO) current debt and financial health profile: Total debt stands at $130.96B. The debt-to-equity ratio is 67.49, which is moderate and generally manageable for most companies. The current ratio is 0.80, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.54. The company holds $26.96B in cash and equivalents. Free cash flow is positive at $376.88M, providing a cushion for debt servicing and shareholder returns.